MPLT
MapLight Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.10B
P/E Ratio
—
EPS
$-18.56
Beta
—
52W High
$24.15
52W Low
$12.24
50-Day MA
$18.20
200-Day MA
$17.51
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. is a pioneering biotechnology firm focused on advancing novel therapies for serious neurological and psychiatric disorders. Leveraging its proprietary platform, the company targets complex biological pathways to develop transformative treatment solutions that aim to significantly improve patient outcomes. With a strong dedication to scientific excellence and a robust clinical development pipeline, MapLight is strategically positioned to tackle critical unmet medical needs, establishing itself as a prominent entity in the rapidly evolving neurotherapeutics landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-168.50M |
| Operating Margin | 0.00% |
| Return on Equity | -56.20% |
| Return on Assets | -34.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $10.41 |
| Price-to-Book | 1.96 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $42.44M |
| Float | $12.74M |
| % Insiders | 52.27% |
| % Institutions | 52.83% |
Analyst Ratings
Consensus ($31.80 target)
1
Strong Buy3
BuyData last updated: 4/8/2026